M

M3 Wake Research | Tucson Neuroscience Research

Research site

(Unclaimed)

Location

6567 East Carondelet, Suite 475, Tucson, Arizona, United States of America

Site insights

Top conditions

Top treatments

ABP-671

Semaglutide

Rimegepant

Pimavanserin

Zavegepant

Semagludtide

Glucose

JNJ-40411813

Azeliragon

Levetiracetam

Parent organization

This site is a part of M3 Wake Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 24 total trials

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting

Early Alzheimer´s Disease

Drug: Placebo (semaglutide)

Drug: Semaglutide

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting

Early Alzheimer's Disease

Drug: Placebo (semaglutide)

Drug: Semagludtide

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting

Alzheimer's Disease (AD)

Drug: Placebo

Drug: ABBV-916

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare th...

Active, not recruiting

Gout

Other: Placebo

Drug: Allopurinol

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Active, not recruiting

Alzheimer Disease, Early Onset

Other: Placebo

Drug: BMS-986446